Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@article{Goldstein1997IneffectivenessON,
  title={Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.},
  author={David John Goldstein and Ou Wang and Joel R. Saper and Randall Stoltz and Stephen David Silberstein and Ninan T. Mathew},
  journal={Cephalalgia : an international journal of headache},
  year={1997},
  volume={17 7},
  pages={785-90}
}
Lanepitant is a high-affinity, selective neurokinin-1 receptor (NK-1) and is effective in the dural inflammation model of acute migraine. Lanepitant 30, 80, and 240 mg given orally was evaluated in a double-blind, placebo-controlled crossover study to determine its effect in reducing migraine pain and severity of associated symptoms. Outpatients treated four migraine headaches of moderate or severe pain intensity with study drug according to a randomization schedule. They recorded their pain… CONTINUE READING
53 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

Similar Papers

Loading similar papers…